These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 36982415)

  • 1. A New Signature That Predicts Progression-Free Survival of Clear Cell Renal Cell Carcinoma with Anti-PD-1 Therapy.
    Lin J; Cai Y; Ma Y; Pan J; Wang Z; Zhang J; Liu Y; Zhao Z
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982415
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Klümper N; Ralser DJ; Zarbl R; Schlack K; Schrader AJ; Rehlinghaus M; Hoffmann MJ; Niegisch G; Uhlig A; Trojan L; Steinestel J; Steinestel K; Wirtz RM; Sikic D; Eckstein M; Kristiansen G; Toma M; Hölzel M; Ritter M; Strieth S; Ellinger J; Dietrich D
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
    Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
    J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a novel gene signature to predict prognosis and response to PD-1 blockade in clear cell renal cell carcinoma.
    Yin X; Wang Z; Wang J; Xu Y; Kong W; Zhang J
    Oncoimmunology; 2021; 10(1):1933332. PubMed ID: 34262797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of LD-related genes signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
    Jia Y; Dong X; Yang F; Zhou L; Long H
    BMC Nephrol; 2024 Sep; 25(1):298. PubMed ID: 39256647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analysis of cellular senescence-related genes in the prognosis, tumor microenvironment, and immunotherapy/chemotherapy of clear cell renal cell carcinoma.
    Lu C; Wang Y; Nie L; Chen L; Li M; Qing H; Li S; Wu S; Wang Z
    Front Immunol; 2022; 13():934243. PubMed ID: 36189255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of overall survival based upon a new ferroptosis-related gene signature in patients with clear cell renal cell carcinoma.
    Sun Z; Li T; Xiao C; Zou S; Zhang M; Zhang Q; Wang Z; Zhan H; Wang H
    World J Surg Oncol; 2022 Apr; 20(1):120. PubMed ID: 35422048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A DNA Damage Repair Gene Signature Associated With Immunotherapy Response and Clinical Prognosis in Clear Cell Renal Cell Carcinoma.
    Peng L; Liang J; Wang Q; Chen G
    Front Genet; 2022; 13():798846. PubMed ID: 35656315
    [No Abstract]   [Full Text] [Related]  

  • 9. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
    Büttner FA; Winter S; Stühler V; Rausch S; Hennenlotter J; Füssel S; Zastrow S; Meinhardt M; Toma M; Jerónimo C; Henrique R; Miranda-Gonçalves V; Kröger N; Ribback S; Hartmann A; Agaimy A; Stöhr C; Polifka I; Fend F; Scharpf M; Comperat E; Wasinger G; Moch H; Stenzl A; Gerlinger M; Bedke J; Schwab M; Schaeffeler E
    Genome Med; 2022 Sep; 14(1):105. PubMed ID: 36109798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel immune-related signature based on immune cells for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
    Zhou L; Fang H; Yin M; Long H; Weng G
    J Clin Lab Anal; 2022 Jun; 36(6):e24409. PubMed ID: 35441741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a claudin-low subtype in clear cell renal cell carcinoma with implications for the evaluation of clinical outcomes and treatment efficacy.
    Zhang C; Li Y; Qian J; Zhu Z; Huang C; He Z; Zhou L; Gong Y
    Front Immunol; 2022; 13():1020729. PubMed ID: 36479115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction of a ferroptosis-related signature based on seven lncRNAs for prognosis and immune landscape in clear cell renal cell carcinoma.
    Wei SY; Feng B; Bi M; Guo HY; Ning SW; Cui R
    BMC Med Genomics; 2022 Dec; 15(1):263. PubMed ID: 36528763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Prognostic Biomarkers for Clear Cell Renal Cell Carcinoma (ccRCC) by Transcriptomics.
    Zhang S; Xu X; Wang Y; Zhu Y; Wang J; Wang H; Guo J
    Ann Clin Lab Sci; 2021 Sep; 51(5):597-608. PubMed ID: 34686501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DDX39 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with clear cell renal cell carcinoma.
    Bao Y; Jiang A; Dong K; Gan X; Gong W; Wu Z; Liu B; Bao Y; Wang J; Wang L
    Int J Biol Sci; 2021; 17(12):3158-3172. PubMed ID: 34421357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction of the metabolic reprogramming-associated gene signature for clear cell renal cell carcinoma prognosis prediction.
    Tai R; Leng J; Li W; Wu Y; Yang J
    BMC Urol; 2023 Sep; 23(1):147. PubMed ID: 37715154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment of a Seven-Gene Signature Associated with CD8
    Chen Y; Zhou X; Xie Y; Wu J; Li T; Yu T; Pang Y; Du W
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cuproptosis-associated 13 gene signature as a robust predictor for outcome and response to immune- and targeted-therapies in clear cell renal cell carcinoma.
    Yuan H; Qin X; Wang J; Yang Q; Fan Y; Xu D
    Front Immunol; 2022; 13():971142. PubMed ID: 36131921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors.
    Zhou JG; Donaubauer AJ; Frey B; Becker I; Rutzner S; Eckstein M; Sun R; Ma H; Schubert P; Schweizer C; Fietkau R; Deutsch E; Gaipl U; Hecht M
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune regulation and prognosis indicating ability of a newly constructed multi-genes containing signature in clear cell renal cell carcinoma.
    Gui Z; Du J; Wu N; Shen N; Yang Z; Yang H; Wang X; Zhao N; Zeng Z; Wei R; Ma W; Wang C
    BMC Cancer; 2023 Jul; 23(1):649. PubMed ID: 37438709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of a combined hypoxia- and metabolism-related prognostic signature to predict clinical prognosis and immunotherapy responses in clear cell renal cell carcinoma.
    Wu X; Xie W; Gong B; Fu B; Chen W; Zhou L; Luo L
    Front Oncol; 2023; 13():1162846. PubMed ID: 38023248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.